Osteotech stops polymer research:
This article was originally published in Clinica
Osteotech has discontinued its polymer R&D programme which included the development of an adhesion barrier and an artificial skin product. Furthermore, the company has stopped marketing its OsteoActive bone substitute. The bone void filler was launched in Europe in late 1995. The measures are part of a restructuring programme to cut spending by more than $1 million a year and to make the European operations profitable. Osteotech will focus on building its revenues by producing ceramic and titanium plasma spray coating services and ceramic powders and products.
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.